Expanding the Novel ADC Target Landscape Through Multimodal Data-Informed Proteomics in Tumor Tissue
- Identifying high confidence novel targets via innovative proteomic platforms that uncover masked targets
- Explaining modality-agnostic strategies to validate high-priority ADC and other targets across indications
- Identifying and validating the patient landscape through parallel clinico-genomic and wet lab insights built upon >500K molecularly-profiled and clinical-data-linked tissues